Key result
OPTIMAL-REPERFUSION tests reduced-dose facilitated PCI versus standard pharmacoinvasive treatment for 30-day major events in STEMI.
Why the study?
The optimal reperfusion strategy for STEMI patients with anticipated PPCI delay is uncertain, as standard pharmacoinvasive strategies carry potential delays between clinical patency and complete myocardial perfusion.
Does a reduced-dose facilitated PCI strategy improve clinical outcomes in STEMI patients with anticipated PPCI delay?
RCT (n=632)
Open-label
randomized
Yes
Does a reduced-dose facilitated PCI strategy improve clinical outcomes in STEMI patients with anticipated PPCI delay?
No takes yet. Share an insight, caveat, or question.
The OPTIMAL-REPERFUSION trial is designed to evaluate whether a reduced-dose facilitated PCI strategy improves clinical outcomes in STEMI patients facing PCI delays.
Chen et al. (2021) conducted an RCT in acute ST-segment elevation myocardial infarction (STEMI) (n=632). Reduced-dose facilitated PCI strategy vs. Standard pharmacoinvasive treatment was evaluated on Composite of death, reinfarction, refractory ischemia, congestive heart failure, or cardiogenic shock at 30-days. The OPTIMAL-REPERFUSION trial is designed to randomize 632 STEMI patients to a reduced-dose facilitated PCI strategy versus standard pharmacoinvasive treatment to evaluate 30-day composite outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: